Dr.Monisha R V, M21612
AIM
To study the improvement in Best Corrected Visual Acuity(BCVA) in patients receiving intravenous methyl prednisolone pulse therapy for various causes of acute uveitis and scleritis.
METHODS
Retrospectively, in 53 eyes affected with uveitis or scleritis, BCVA at the time of presentation was compared with BCVA at 1 week and 4 weeks after receiving intravenous methyl prednisolone. The cases included were granulomatous uveitis, acute attack of Vogt-Koyanagi Harada syndrome, necrotising scleritis, posterior scleritis and choroiditis.
RESULTS
39.6%(n=21) of eyes showed improved BCVA in first week which further increased to 52.1%(n=25) by fourth week after intravenous methyl prednisolone therapy. There were no ocular or systemic side effects.
CONCLUSION
Intravenous methyl prednisolone plays an effective role in the management of intraocular inflammation and thus aids in the improvement of visual function.
Leave a Comment